维布妥昔单抗联合化疗一线治疗新诊断III和IV期霍奇金淋巴瘤的成本效果分析
基于ECHELON-1试验数据构建Markov决策分析模型,从美国支付方角度比较AVD+BV方案与ABVD方案一线治疗III或IV期霍奇金淋巴瘤的成本效果。AVD+BV较ABVD增加0.56个质量调整生命年,但终身医疗费用显著更高(361,137美元 vs 184,291美元),增量成本效果比为每QALY 317,254美元。结论认为在当前药品定价下,以BV替代博来霉素一线治疗不太可能具有成本效果。
要点
- AVD+BV较ABVD增加0.56个QALY,但终身费用更高(361,137美元 vs 184,291美元)。
- AVD+BV的增量成本效果比为每QALY 317,254美元。
- 若实施适应证特异性定价,一线BV采购成本需降低56%至73%才能使ICER分别达到每QALY 150,000美元至100,000美元。
核心结论
- 在当前药品定价下,以BV替代博来霉素一线治疗III或IV期霍奇金淋巴瘤不太可能具有成本效果。
- 若实施适应证特异性定价,一线BV需大幅降价才能将ICER降至更广泛接受的水平。
研究设计与样本
- 基于ECHELON-1随机开放标签试验数据构建Markov决策分析模型。
- 比较AVD+BV与ABVD一线治疗III或IV期霍奇金淋巴瘤队列的成本与临床结局。
- 从美国支付方角度计算终身直接医疗费用、QALY和ICER。
主要发现
- AVD+BV较ABVD增加0.56个QALY。
- AVD+BV终身医疗费用为361,137美元,ABVD为184,291美元。
- AVD+BV的ICER为每QALY 317,254美元。
- 若实施适应证特异性定价,一线BV采购成本需降低56%至73%才能使ICER分别达到每QALY 150,000美元至100,000美元。
关键数值与推荐
- BV价格为每50毫克瓶6,970美元。
- AVD+BV较ABVD增加0.56个QALY。
- AVD+BV终身费用361,137美元 vs ABVD 184,291美元。
- AVD+BV的ICER为每QALY 317,254美元。
- 一线BV采购成本需降低56%至73%以使ICER分别达到每QALY 150,000美元至100,000美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In a recent randomized, open-label trial (ECHELON-1), brentuximab vedotin (BV) combined with doxorubicin, vinblastine, and dacarbazine (AVD+BV) decreased the risk of progression in adults diagnosed with stage III or IV Hodgkin lymphoma (HL) compared with standard bleomycin-containing chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]). However, the cost effectiveness of incorporating BV (US$6,970 per 50-mg vial) into the first-line setting is unknown. PATIENTS AND METHODS: We constructed a Markov decision-analytic model to measure the costs and clinical outcomes for AVD+BV compared with ABVD as first-line therapy in a cohort of patients with stage III or IV HL. Transition probabilities were estimated from ECHELON-1 by fitting parametric survival distributions. Lifetime direct health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for AVD+BV compared with ABVD from a US payer perspective. Our model was also used to estimate BV price reductions that would achieve more favorable cost effectiveness under indication-specific pricing. RESULTS: AVD+BV was associated with an improvement of 0.56 QALYs compared with treatment with standard ABVD. However, incorporating BV into first-line therapy led to significantly higher lifetime health care costs ($361,137 v $184,291), causing the ICER for AVD+BV to be $317,254 per QALY. If indication-specific pricing were implemented, acquisition costs for BV used in the first-line setting would need to be reduced by 56% to 73% for ICERs of $150,000 to $100,000 per QALY, respectively. CONCLUSION: Substituting BV for bleomycin during first-line therapy for stage III or IV HL is unlikely to be cost effective under current drug pricing. Should indication-specific pricing be implemented, significant price reductions for BV used in the first-line setting would be needed to reduce ICERs to more widely acceptable values.
引用
- Huntington SF, von Keudell G, Davidoff AJ, et al. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. J Clin Oncol. 2018. PMID: 30285558. doi:10.1200/JCO.18.00122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。